Shanghai Pharmaceuticals Holding (02607): SOPH's Thiostrepton Sulfate Injection passes generic drug consistency evaluation.

Shanghai Pharmaceuticals Holding (02607) announced that recently, its subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Hefeng Pharmaceuticals") received the "Drug Supplementary Application Approval Notice" (Notice No.: 2026B01918) issued by the National Medical Products Administration for its injection of Tazobactam Sodium. The drug has passed the generic drug consistency evaluation. It is reported that the injection of Tazobactam Sodium is used for sepsis, bacteremia, central nervous system infections (including meningitis) caused by Pseudomonas aeruginosa, Proteus species, Escherichia coli, Klebsiella species, Enterobacter species, Serratia species, complicated and recurrent urinary tract infections, lung infections, intra-abdominal infections (including peritonitis), bone infections, burns, skin and soft tissue infections, or in combination with other antibacterial drugs for severe Staphylococcus aureus infections (resistant to methicillin strains). In January 2025, Hefeng Pharmaceuticals submitted a supplementary application to the National Medical Products Administration for the generic quality and efficacy consistency evaluation of this drug and it was accepted. As of the date of this announcement, the company has invested approximately RMB 4.38 million in research and development expenses for the consistency evaluation of this drug. According to national policies, varieties that pass the consistency evaluation will receive greater support in medical insurance payments and procurement by medical institutions. Therefore, the injection of Tazobactam Sodium by Hefeng Pharmaceuticals, which has passed the generic drug consistency evaluation, will help expand the market share of this drug, enhance market competitiveness, and accumulate valuable experience for the company's subsequent products in conducting generic drug consistency evaluations.